JPS6220982B2 - - Google Patents

Info

Publication number
JPS6220982B2
JPS6220982B2 JP54056229A JP5622979A JPS6220982B2 JP S6220982 B2 JPS6220982 B2 JP S6220982B2 JP 54056229 A JP54056229 A JP 54056229A JP 5622979 A JP5622979 A JP 5622979A JP S6220982 B2 JPS6220982 B2 JP S6220982B2
Authority
JP
Japan
Prior art keywords
formula
group
oxo
acetic acid
lactam
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP54056229A
Other languages
English (en)
Japanese (ja)
Other versions
JPS54154760A (en
Inventor
Rodoriguetsu Rudobitsuku
Marusharu Rushen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB SA filed Critical UCB SA
Publication of JPS54154760A publication Critical patent/JPS54154760A/ja
Publication of JPS6220982B2 publication Critical patent/JPS6220982B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C07D223/10—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D227/00—Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups C07D203/00 - C07D225/00
    • C07D227/02—Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups C07D203/00 - C07D225/00 with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D227/06—Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups C07D203/00 - C07D225/00 with only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D227/08—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polyamides (AREA)
JP5622979A 1978-05-08 1979-05-08 Lactammnnacetic acid or its amide and said manufacture Granted JPS54154760A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1816078 1978-05-08

Publications (2)

Publication Number Publication Date
JPS54154760A JPS54154760A (en) 1979-12-06
JPS6220982B2 true JPS6220982B2 (enExample) 1987-05-11

Family

ID=10107678

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5622979A Granted JPS54154760A (en) 1978-05-08 1979-05-08 Lactammnnacetic acid or its amide and said manufacture

Country Status (23)

Country Link
US (1) US4221789A (enExample)
EP (1) EP0005689B1 (enExample)
JP (1) JPS54154760A (enExample)
AT (1) ATE27T1 (enExample)
AU (1) AU522815B2 (enExample)
BE (1) BE876067A (enExample)
CA (1) CA1119593A (enExample)
DE (2) DE2960194D1 (enExample)
DK (1) DK150064C (enExample)
ES (1) ES480299A1 (enExample)
FI (1) FI66602C (enExample)
FR (1) FR2425433A1 (enExample)
GR (1) GR67631B (enExample)
HU (1) HU178362B (enExample)
IT (1) IT7948950A0 (enExample)
NL (1) NL7903536A (enExample)
NO (1) NO150639C (enExample)
PL (1) PL117056B1 (enExample)
PT (1) PT69582A (enExample)
SE (1) SE7903864L (enExample)
SU (2) SU1093245A3 (enExample)
YU (1) YU41340B (enExample)
ZA (1) ZA792175B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2944456C2 (de) * 1979-11-03 1982-04-01 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von N-α -Alkoxyalkyl-carbonsäureamiden
US4396616A (en) * 1981-09-04 1983-08-02 Merck & Co., Inc. Substituted enantholactam derivatives as antihypertensives
EP0089900B1 (en) * 1982-03-24 1985-12-27 Prodes S.A. New n-((2-oxo-1-pyrrolidinyl)acetyl)piperazines, the methods of producing such new compounds and their salts as well as pharmaceutical preparations for therapeutic use containing these compounds or salts
US4608201A (en) * 1984-05-21 1986-08-26 Ppg Industries, Inc. Process for preparing lactam imides
CA1322199C (en) * 1987-07-15 1993-09-14 Masami Eigyo N-¬(2-oxopyrrolidin-1-yl) acetyl)| piperazine derivatives and drug for senile dementia
IT1242043B (it) * 1990-12-21 1994-02-02 Sigma Tau Ind Farmaceuti Derivati della 1,2,3,4,-tetraidronaftilammina ad attivita' nootropica e composizioni farmaceutiche che li contengono.
IT1245870B (it) * 1991-06-05 1994-10-25 Sigma Tau Ind Farmaceuti 3-acilammino-2-pirrolidinoni quali attivatori dei processi di appremdimento e della memoria e composizioni farmaceutiche comprendenti tali composti
US5510477A (en) * 1994-03-01 1996-04-23 The Procter & Gamble Company Process for the acylation of lactams
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
AU1369001A (en) * 1995-12-13 2001-03-22 Abbott Laboratories Retroviral protease inhibiting compounds
US7834043B2 (en) 2003-12-11 2010-11-16 Abbott Laboratories HIV protease inhibiting compounds
DK2346500T3 (en) * 2008-10-16 2017-07-17 Univ Johns Hopkins Methods and compositions for improving cognitive function
EP2533645B1 (en) * 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
EP2968220B1 (en) 2013-03-15 2021-05-05 Agenebio, Inc. Methods and compositions for improving cognitive function
MX384391B (es) 2015-05-22 2025-03-14 Agenebio Inc Composiciones farmacéuticas de levetiracetam de liberación extendida.
JP6785838B2 (ja) 2015-08-05 2020-11-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 新規な置換グリシン誘導のｆｘｉａ阻害剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2657215A (en) * 1950-03-10 1953-10-27 Goodrich Co B F Method for the preparation of novel n-(2-carboxyalkyl) succinimides
DE1081896B (de) * 1959-03-28 1960-05-19 Bayer Ag Verfahren zur Herstellung von ª‡-Amino-ª‰-hydroxycarbonsaeuren
GB1039113A (en) 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
GB1309692A (en) 1970-02-13 1973-03-14 Ucb Sa N-substituted lactams
US3751262A (en) * 1970-06-30 1973-08-07 Allied Chem Ruminant feed supplement
GB1539817A (en) * 1976-10-22 1979-02-07 Ucb Sa N-substituted lactams

Also Published As

Publication number Publication date
AU522815B2 (en) 1982-06-24
DE2960194D1 (en) 1981-04-16
ES480299A1 (es) 1980-08-16
DK182379A (da) 1979-11-09
ZA792175B (en) 1980-05-28
SU1093245A3 (ru) 1984-05-15
NL7903536A (nl) 1979-11-12
SU969701A1 (ru) 1982-10-30
FI66602C (fi) 1984-11-12
FI66602B (fi) 1984-07-31
FI791421A7 (fi) 1979-11-09
EP0005689A1 (fr) 1979-11-28
PL215420A1 (enExample) 1980-02-11
NO791477L (no) 1979-11-09
AU4681679A (en) 1979-11-15
BE876067A (fr) 1979-11-07
NO150639B (no) 1984-08-13
US4221789A (en) 1980-09-09
YU41340B (en) 1987-02-28
PT69582A (fr) 1979-06-01
DK150064C (da) 1987-06-15
CA1119593A (en) 1982-03-09
JPS54154760A (en) 1979-12-06
YU106979A (en) 1983-04-30
IT7948950A0 (it) 1979-05-07
GR67631B (enExample) 1981-09-01
DE2918523A1 (de) 1979-11-15
EP0005689B1 (fr) 1981-03-18
SE7903864L (sv) 1979-11-09
DK150064B (da) 1986-12-01
PL117056B1 (en) 1981-07-31
HU178362B (en) 1982-04-28
FR2425433A1 (fr) 1979-12-07
NO150639C (no) 1984-11-21
ATE27T1 (de) 1981-04-15

Similar Documents

Publication Publication Date Title
JPS6220982B2 (enExample)
US3978045A (en) N2 -dansyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof
IE911683A1 (en) "New aminopiperidine, aminopyrrolidine and aminoperhydroazepine compounds processes for the preparation thereof and pharmaceutical compositions containing them"
CA1242439A (en) 1-¬(AMINOALKYL AND AMINOALKYLAMINO)CARBONYL AND THIOCARBONYL|-.alpha.,.alpha.-DIARYLPYRROLIDINE, PIPERIDINE AND HOMOPIPERIDINEACETAMIDES AND ACETONITRILES
CA1323874C (en) Pyroglutamide derivatives
PL84346B1 (en) 3-aroyl-alkenyleneimines[us3835149a]
CA1079277A (en) 10(.omega.-(BENZOYLPIPERIDINYL)ALKYL) PHENOTHIAZINES
CA2530310C (en) Substituted diketopiperazines and their use as oxytocin antagonists
FI71936B (fi) Foerfarande foer framstaellning av neuroleptiskt aktiva 2-substituerade-8-fluor-5-(4-fluorfenyl)-2,3,4,4a 5,9b-hexahydro-4a 9b-trans-1h-pyrido/4,3-b/indolderivat
US4324791A (en) Heterocyclic antidiarrheal compositions & methods of use
NO163597B (no) Styreinnretning for et ett-eller tosporet kjoeretoey.
JPH0610192B2 (ja) ビ―２ｈ―ピロール―ジオン化合物
US5449677A (en) Cyclic benzylamino, benzylamido and benzylimido antipsychotic agents
JPS5839148B2 (ja) Ｎ−置換２−ピロリジノンおよび同製造法
US2555353A (en) 3-tertiaryaminoalkyl-2-pyrrolidones and process for preparing same and related products
EP0412058B1 (en) 1-acyl-2-pyrrolidinones as enhancers of learning and memory and pharmaceutical compositions containing same
US4505920A (en) Certain N-substituted-4-aryl-3,5-pyridine dicarboxylates and their antihypertensive use
JPH0780888B2 (ja) ピロロ〔１，２−ａ〕〔４，１〕ベンゾオキサゼピン誘導体
DE68907845T2 (de) Verbrückte bicyclische 4-(4-(3-Benzisothiazolyl)-1-piperazinyl)-butylimide mit antipsychotischer Wirkung.
KR950007591B1 (ko) 피로글루타미드 유도체
KR880001715B1 (ko) 1-푸릴-3,4-디하이드로이소퀴놀린의 제조방법
SU862825A3 (ru) Способ получени 3- 4-(2 -пиридил)-пиперазин-1-ил -1-(3,4,5-триметоксибензоилокси)пропана или его дигидрохлорида
CA1123852A (en) Cyclododecane derivatives and a process for the preparation thereof
JPH0532622A (ja) 大脳保護効果を有するｎ−アシル−４−フエニル−ピロリジン−２−オンの製造方法
US3423415A (en) 4 - (n - (3,3 - diphenyl - propyl) - amino) - 1-methyl-3-phenyl-piperidine and intermediates thereto